company background image
EW logo

Edwards Lifesciences NYSE:EW Voorraadrapport

Laatste prijs

US$70.48

Marktkapitalisatie

US$41.6b

7D

4.0%

1Y

3.8%

Bijgewerkt

24 Nov, 2024

Gegevens

Financiële gegevens bedrijf +

Edwards Lifesciences Corporation

NYSE:EW Voorraadrapport

Marktkapitalisatie: US$41.6b

EW Overzicht aandelen

Edwards Lifesciences Corporation levert producten en technologieën voor structurele hartaandoeningen en bewaking van kritieke zorg in de Verenigde Staten, Europa, Japan en internationaal. Meer informatie

Beloningen

De koers-winstverhouding ( 26.5 x) ligt onder het gemiddelde van de Medical Equipment -industrie ( 37.2 x)

De winst groeide het afgelopen jaar met 21.7%

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

Geen risico's gedetecteerd voor EW uit onze risicocontroles.

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WA
WarrenAI
Based on Analyst Price Targets

SAPIEN M3 And EVOQUE Launches Propel Heart Therapies To New Heights In Global Expansion

Key Takeaways Expanding treatment options and introducing new valve sizes should drive revenue growth by covering more patient needs and increasing market adoption. Strategic acquisitions and restructuring efforts enhance focus on heart therapies, potentially boosting revenue and improving resource allocation.
View narrative
US$76.39
FV
7.7% undervalued intrinsic discount
4.14%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
4 days ago author updated this narrative

Edwards Lifesciences Corporation Concurrenten

GE HealthCare Technologies

NasdaqGS:GEHC

US$37.7b

IDEXX Laboratories

NasdaqGS:IDXX

US$34.2b

ResMed

NYSE:RMD

US$35.8b

Becton Dickinson

NYSE:BDX

US$64.7b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Edwards Lifesciences
Historische aandelenkoersen
Huidige aandelenkoersUS$70.48
52 Week HoogtepuntUS$96.12
52 Week LaagUS$58.93
Bèta1.12
11 maand verandering1.59%
3 maanden verandering2.52%
1 Jaar Verandering3.80%
33 jaar verandering-35.65%
5 jaar verandering-13.68%
Verandering sinds IPO5,025.82%

Recent nieuws en updates

Estimating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Nov 11
Estimating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Edwards Lifesciences Q3: Divesting Critical Care And Focusing On Structural Hearts

Oct 25

Recent updates

Estimating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Nov 11
Estimating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Edwards Lifesciences Q3: Divesting Critical Care And Focusing On Structural Hearts

Oct 25

Bearish: Analysts Just Cut Their Edwards Lifesciences Corporation (NYSE:EW) Revenue and EPS estimates

Sep 11
Bearish: Analysts Just Cut Their Edwards Lifesciences Corporation (NYSE:EW) Revenue and EPS estimates

Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future

Aug 30
Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future

Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?

Aug 17
Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?

Edwards Lifesciences Q2: Buy The Dip Amid Guidance Cut

Jul 26

Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Jul 26
Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Why Investors Shouldn't Be Surprised By Edwards Lifesciences Corporation's (NYSE:EW) P/E

Jul 12
Why Investors Shouldn't Be Surprised By Edwards Lifesciences Corporation's (NYSE:EW) P/E

Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Jun 24
Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Edwards Lifesciences Corp Looks Bullish (Technical Analysis)

Jun 22

Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future

May 13
Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future

Edwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)

May 09

When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?

Apr 29
When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?

Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Apr 15
Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear

Apr 01
Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear

Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture

Feb 21
Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture

Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained)

Feb 14

Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47

Feb 08
Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47

Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly

Jan 28
Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly

The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing

Jan 14
The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing

Edwards Lifesciences: Undervalued With A Substantial Upside Potential

Jan 09

Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up

Dec 31
Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up

Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)

Dec 17
Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)

Edwards Lifesciences: Sector Derating A Bigger Threat Than Competition Or Slowing Markets

Oct 26

Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Oct 23
Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?

Oct 09
Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?

Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value

Sep 26
Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value

A Look At The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Sep 11
A Look At The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Edwards Lifesciences: Rising Dominance In Structural Heart Disease

Aug 21

Rendement voor aandeelhouders

EWUS Medical EquipmentUS Markt
7D4.0%1.5%2.2%
1Y3.8%20.8%31.6%

Rendement versus industrie: EW presteerde slechter dan de US Medical Equipment -sector, die het afgelopen jaar een rendement van 20.8 % opleverde.

Rendement versus markt: EW presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 31.6 % opleverde.

Prijsvolatiliteit

Is EW's price volatile compared to industry and market?
EW volatility
EW Average Weekly Movement3.7%
Medical Equipment Industry Average Movement8.1%
Market Average Movement6.3%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.1%

Stabiele aandelenkoers: EW heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van EW is het afgelopen jaar stabiel geweest.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
195819,800Bernard Zovighianwww.edwards.com

Edwards Lifesciences Corporation levert producten en technologieën voor structurele hartaandoeningen en kritieke zorgbewaking in de Verenigde Staten, Europa, Japan en internationaal. Het bedrijf biedt transkatheter hartklepvervangingsproducten voor de minimaal invasieve vervanging van aortahartkleppen onder de naam Edwards SAPIEN klepsysteem; en transkatheter hartklepreparatie- en vervangingsproducten voor de behandeling van mitralisklep- en tricuspidalisklepaandoeningen onder de namen PASCAL PRECISION en Cardioband. Het bedrijf biedt ook chirurgische structurele hartoplossingen, zoals de chirurgische aortaklep onder de naam INSPIRIS; de aortaklep INSPIRIS RESILLA, met RESILIA weefsel- en VFit-technologie; KONECT RESILIA, een voorgemonteerde weefselklepconduitatie voor complexe gecombineerde procedures; en de MITRIS RESILIA-klep.

Edwards Lifesciences Corporation Samenvatting

Hoe verhouden de winst en inkomsten van Edwards Lifesciences zich tot de beurswaarde?
EW fundamentele statistieken
MarktkapitalisatieUS$41.57b
Inkomsten(TTM)US$1.57b
Inkomsten(TTM)US$6.31b

26.5x

Koers/Winstverhouding

6.6x

P/S-verhouding

Is EW overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
EW resultatenrekening (TTM)
InkomstenUS$6.31b
Kosten van inkomstenUS$1.48b
BrutowinstUS$4.84b
Overige uitgavenUS$3.27b
InkomstenUS$1.57b

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)2.66
Brutomarge76.60%
Nettowinstmarge24.82%
Schuld/Eigen Vermogen Verhouding6.2%

Hoe presteerde EW op de lange termijn?

Bekijk historische prestaties en vergelijking